The biotechnology company Eisai Co., Ltd. announced a rolling submission for accelerated approval from the Food and Drug Administration for their anti-amyloid Alzheimer’s treatment,…
Cassava Sciences revealed positive clinical data from their simufilam trial, a potentially disease-modifying therapy for treating Alzheimer’s. Their preliminary study showed that simufilam significantly…
In the 1990s, the idea that clumps of beta-amyloid proteins are the main culprits of Alzheimer’s took off, and this line of thought —…
UPDATE: 3 March 2024, 8:22 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Today, the experimental Eli Lilly drug donanemab received the FDA’s “breakthrough therapy designation” based on its potential to treat Alzheimer’s disease. The FDA granted…
Looking for answers about Alzheimer’s treatment Aduhelm (generic name aducanumab)? Here’s a primer on what it is, what it does, and more, according to…
Cinical trial investigators for aducanumab (Aduhelm) discuss the significance of the drug’s recent FDA approval, the controversy surrounding its efficacy, and the uncertainty ahead….
Geri Taylor, a participant in the aducanumab (Aduhelm) clinical trial, and her husband Jim share insights about taking part in the research. UPDATE: 3…
Biogen’s aducanumab — a human antibody-based drug that targets beta-amyloid plaques, which are found in the brains of people with Alzheimer’s — has gone…
In case you missed them, our editors and contributors round up their most recommended reads from the month of April in Being Patient Reads…